KDMN - The Buzz Show: Kadmon Holdings Inc. (NASDAQ: KDMN) Definitive Merger Agreement with Sanofi

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi

Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering into a definitive merger agreement with Sanofi.

Shareholders of Kadmon common stock will receive $9.50 per share in cash, representing a total equity value of approximately $1.9 billion, while the acquisition will support Sanofi’s strategy to continue to grow its General Medicines core assets and immediately add Rezurock (belumosudil) to its transplant portfolio.

Kadmon is a biopharmaceutical company that discovers, develops, and delivers transformative therapies for unmet medical needs. Rezurock (belumosudil), an oral, once-daily tablet, is approved in the United States for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

For more information, please visit: Kadmon Holdings, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Kadmon Holdings, Inc. (NASDAQ: KDMN) Definitive Merger Agreement with Sanofi first appeared on Financial Buzz .

For further details see: